anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject vaccine intended to prevent Pseudomonas aeruginosa infection and containing a specific antigenic peptide. SOLUTION: This vaccine contains a peptide having an amino acid sequence of the formula as immunodominant epitope. The peptide, which includes natural γ-globulin, is specifically reactive, in sufficiently high potency, with the antibody in the serum of a patient infected with Pseudomonas aeruginosa; therefore, can be used as an excellent vaccine for preventing Pseudomonas aeruginosa infection as a new immunodominant eptiope. In this case, its dose is each 2-40μg/kg three times at two-day intervals through intramuscular administration. For a immunoglobulin preparation, it is generally administered intravenously, its dose being 0.1-1,000mg/kg body weight a day per adult. Use of this peptide as an antigen affords an antibody.
BACKGROUND: Inflammatory type focal cerebral arteriopathy (FCA-i) in the anterior circulation (AC) is well characterized, and the focal cerebral arteriopathy severity score (FCASS) reflects the severity of the disease. We identified cases of FCA-i in the posterior circulation (PC) and adapted the FCASS to describe these cases.
METHODS: In this comparative cohort study, patients from the Swiss NeuroPaediatric Stroke Registry with ischemic stroke due to FCA-i between January 2000 and December 2018 were analyzed. A comparison between PC and AC cases regarding pediatric National Institutes of Health Stroke Scale score and pediatric stroke outcome measure and FCASS was performed. We estimated infarct size by the modified pediatric Alberta Stroke Program Early Computed Tomography Score in children with AC stroke and the adapted Bernese posterior diffusion-weighted imaging score in the PC.
RESULTS: Thirty-five children with a median age of 6.3 (interquartile range, 2.7-8.2 [95% CI, 0.9-15.6]; 20 male; 57.1%) years with FCA-i were identified. The total incidence rate was 0.15/100 000/year (95% CI, 0.11-0.21). Six had PC-FCA-i. Time to final FCASS was longer in the PC compared with AC; the evolution of FCASS did not differ. Initial pediatric National Institutes of Health Stroke Scale score was higher in children with FCA-i in the PC with a median of 10.0 (interquartile range, 5.75-21.0) compared with 4.5 (interquartile range, 2.0-8.0) in those with AC-FCA-i. Different from the anterior cases, PC infarct volume did not correlate with higher discharge, maximum, or final FCASS scores (Pearson correlation coefficient [r], 0.25, 0.35, and 0.54).
CONCLUSIONS: FCA-i also affects the PC. These cases should be included in future investigations into FCA-i. Although it did not correlate with clinical outcomes in our cohort, the modified FCASS may well serve as a marker for the evolution of the arteriopathy in posterior FCA-i.
Nowadays, mother-to-child HIV transmission is the main cause of paediatric HIV infections. Yet, this way of transmission is effectively limited by the use of antiretroviral therapies during pregnancy in HIV infected women. The study TEmAA (ANRS 12109) we conducted allowed us to suggest a therapeutic scheme of administration of the association tenofovir disoproxil fumarate (TDF) - emtricitabine (FTC) to reduce the risk of postpartum resistance that may occur with the administration of a single dose of nevirapine before delivery. However, we also observed a large interindividual variability of TDF in vivo placental transfer that remained unexplained. Placental membrane transporters, including efflux transporters belonging the ABC transporter superfamily and uptake transporters, may constitute a source of variability. In this case, we showed such an association for maraviroc with a significant inverse correlation between its clearance index and the placental expression level of several efflux transporters of the ABCC/MRP family. Regarding TDF, it has been shown that this drug is a substrate of several efflux transporters (ABCC2/MRP2, ABCC4/MRP4, ABCC10/MRP7) and an uptake transporter (hOAT3). As these transporters are expressed on the placental barrier, it may be hypothesized that their expression levels could contribute to modulate the placental transfer of this drug. To test this hypothesis, an ex vivo model known as "the perfused ex vivo cotyledon model" allows to reproduce the conditions of the third trimester of pregnancy. Our first aim is to evaluate the potential effect of ABCC2, ABCC4, ABCC10 and hOAT3 placental expression on TDF placental transfer (First year). We also want to investigate whether a potential interaction between TDF and FTC could take part to variability.
The invention relates to a method for curing cardiovascular diseases by using cells from adipose tissue. The invention provides application of concentrated cell groups including stem cells from fat on preparation of a drug for restoring perfusion and cardiac muscle scare forming reduction after myocardial infarction. Regenerative cells from fat are used for curing patients including patients suffering from cardiovascular diseases or disorder. The method for curing patients comprises steps of treating fat tissue so as to provide concentrated regenerative cells from fat tissue, such as stem cells and progenitor cells, for patients. The method can be applied in a closed system, and then stem cells cannot be exposed on outside environment before the drug is fed to patients. Therefore, in a preferable application mode, regenerative cells from fat and additives for promoting and supporting cardiovascular disease cure are arranged in an acceptor together.
Stage 1 participants will receive a placebo matching solution, administered subcutaneously every 4 weeks, completing the treatment period at Week 45. Stage 2 participants will receive a placebo matching solution, administered subcutaneously every 4 weeks, completing the treatment period at Week 45.
PROBLEM TO BE SOLVED: To provide a novel eIF2α phosphorylation accelerator.SOLUTION: According to the present invention, there is provided a compound represented by the formula (4) or a bupranolol derivative (1-phenoxy-3-alkylamino-propane-2-ol derivative). Here, phosphorylation of eIF2α is promoted through a path different from that of PERK and GCN2. There is also provided a therapeutic agent for the prevention or treatment of metabolism, cranial nerve, cancer, immune disorders. [X and Y each independently represent H, a halogen atom, a C1-4 alkyloxy group, etc., or X and Y together form a 1,2-di-oxyethylene group, etc.; Z represents H, a halogen atom, a C1-4 alkyloxy group, etc.]SELECTED DRAWING: None
Pulmonary hypertension (PH) associated with chronic lung disease (CLD) is both common and underrecognised. The presence of PH in the setting of lung disease has been consistently shown to be associated with worse outcomes. Recent epidemiological studies have advanced understanding of the heterogeneity of this patient population and shown that defining both the specific type of CLD as well as the severity of PH (i.e. deeper phenotyping) is necessary to inform natural history and prognosis. A systematic diagnostic approach to screening and confirmation of suspected PH in CLD is recommended. Numerous uncontrolled studies and one phase 3 randomised, controlled trial have suggested a benefit in treating PH in some patients with CLD, specifically those with fibrotic interstitial lung disease (ILD). However, other studies in diseases such as COPD-PH showed adverse outcomes with some therapies. Given the expanding list of approved pharmacological treatments for pulmonary arterial hypertension, developing a treatment algorithm for specific phenotypes of CLD-PH is required. This article will summarise existing data in COPD, ILD and other chronic lung diseases, and provide recommendations for classification of CLD-PH and approach to the diagnosis and management of these challenging patients.
The present invention discloses a new medicament for treating infantile acute diarrhea, and a preparation method thereof. The medicine uses evodia rutaecarpa, clove, dried ginger, lexon, white atractylodes rhizome, betel nut, coptis and semen plantaginis as raw materials. According to different situations of all the traditional Chinese medicines, the raw materials are respectively and proportionally prepared after the steps of air drying, pulverization, solvent extraction, etc. Then, the raw materials are concentrated, skin penetrable liquid is added, and the mixtures are prepared into paste attached to a rubber cloth similar to a woundplast and applied to acupuncture points. The present invention reduces the pain for taking medicines and having injections for infants, and is easily accepted by children. The present invention adopts the unique recipe and the preparation method, and the medicament has the advantages of easy and convenient use and obvious treating effect.
This group consisted of subjects previously vaccinated with the Prevenar™ vaccine as part of a previous study by GSK Biologicals - the 10PN-PD-DIT-001 (105553) study (EuDRA-CT number: 2005-003300-11). As part of the 105553 study, subjects had received a 3-dose primary vaccination of Synflorix vaccine at 2, 3 and 4 months of age (injected intramuscularly \[IM\] in the right thigh) co-administered with Infanrix hexa™ vaccine, except for the second dose in France, which was co-administered with Infanrix™ IPV Hib, injected intramuscularly in the left thigh. As part of this study, at 12-18 months of age, subjects received a booster dose of Synflorix™, injected IM in the right thigh or deltoid, co-administered with Infanrix hexa™ vaccine, injected IM in the left thigh or deltoid.
Single-dose tocilizumab of 8 mg/kg (maximum dose of 800mg). Best supportive care.
<P>PROBLEM TO BE SOLVED: To provide drugs (preventing agents or treating agents) which are effective for treatments of hypertension, cardiac disease (cardiac hypertrophy, cardiac failure, myocardial infarction, etc.), cerebral apoplexy, nephritis and the like.  <P>SOLUTION: Circulatory disease treatment agents in forms that allow combined use of chymase inhibitors and ACE(angiotensin converting enzyme) inhibitors. Also, circulatory disease treatment agents and angiotensin II production inhibitors which contain each chymase inhibitors alone as an active ingredient. Thiobenzimidazole derivatives are especially effective as the chymase inhibitors, and temocapril hydrochloride is especially effective as the ACE inhibitors.  <P>COPYRIGHT: (C)2008,JPO&INPIT
PURPOSE:To accurately determine trace amounts of immunosuppressive acid protein (IAP) and to apply this method in cancer diagnosis, by method wherein an anti-IAP antibody, having a given concentration, is reacted with a specimen, especially a stepwise diluted solution of urine, and an IAP-sensitized red blood cell is then added to the reaction product to investigate the occurrence of agglomeration. CONSTITUTION:IAP taken from human body fluid is injected to a rabbit, and the obtained immune serum is incorporated into normal human serum to prepare anti- IAP antibody, which is the diluted to a given concentration to prepare a diluted solution of said antibody. Meanwhile, an IAP-sensitized sheep red blood cell is prepared. Said anti-IAP antibody diluted solution is added to a specimen (serum, abdominal dropsy, urine, etc.), especially that obtd. by the addn. of a stepwise diluted solution of urine and incubated at 37 deg.C for about 30min is prepd., and then IAP- sensitized red blood cell PBS-BS liquid is added thereto. After the solution is allowed to stand at a room temperature for 2hr, the occurrence of agglomeration of the red blood cell is checked. The occurrence of agglomeration shows the presence of IAP. This enables the sensitive and accurate detection of IAP which appears especially distinctly in a cancer patient.
This is a prospective cohort study that included 4 different cohorts i.e CKD ,hemodialysis ( HD), continuous ambulatory peritoneal dialysis (CAPD) , kidney transplant (KT) patients and a control group without kidney failure at Faculty of Medicine, Vajira Hospital,Navamindradhiraj University from June -December 2021. The inclusion criteria were CKD stage 3-5 (eGFR \< 60 mL/min/1.73m3), CKD patients receiving HD,CAPD and KT. The participants of the healthy control group consists of volunteer health care workers who had been vaccinated according to the nation vaccination schedule. Participants in both groups needed to be 18-90 years old. The exclusion criteria were allergy to the components of vaccines, unable to receive the vaccine according to the schedule,fever or concomitant serious illnesses and had side effect from the first dose of vaccination. Patients or individuals with prior COVID-19 infection in the past (diagnosed via patients history and serological test for nucleocapsid (NCP) antibody were excluded from the study. The study protocol was approved by the local Ethics Committed and participants were enrolled after written informed consent was obtained. The study who performed in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice. The vaccine used was authorized by the Thai Food and Drug Administration and the Department of Medical Sciences (DMS).
The application provides a compound preparation prepared from moxifloxacin and cimetidine and a preparation method thereof. The active ingredients of the compound preparation comprise moxifloxacin and cimetidine, and the proportion is 0.2-0.4: 0.2 to 0.6. The raw material medicaments are taken according to the corresponding parts by weight, and are added with proper auxiliary materials according to the preparation method of corresponding pharmaceutics, so that the raw material medicaments can be respectively prepared into tablets, capsules, injections and other dosage forms. The moxifloxacin is a fourth-generation fluoroquinolone drug, acts on bacterial DNA gyrase and topoisomerase IV, inhibits the synthesis and replication of DNA, and plays a role in rapid sterilization. Cimetidine is a liver drug enzyme inhibitor, and can delay the metabolism of the combined drug, improve the blood concentration and improve the curative effect of the combined drug. The two are prepared into a compound preparation, the effect of treating infection caused by sensitive bacteria is good, the side effect is low, the medication is safe, the taking is convenient, and the application effect is good.
Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive RAD001 at a dose of 10mg daily p.o. and exemestane 25mg daily p.o. for 48 weeks.
Patients will be treated with 4 cycles of neoadjuvant Opdualag (cohort 1) or Nivolumab (cohort 2) given every 4 weeks followed by surgical resection. There will be an option to proceed directly to surgery after 2 cycles of therapy should patients have frank progression of disease based on clinical evaluation. There will also be an option to continue with Opdualag or Nivolumab beyond 4 cycles if there is ongoing clinical benefit per investigator discretion. If there is clinical evidence of a clinical complete response, patients may forgo surgery per investigator discretion. The primary outcome of pathologic response rate will be assessed at the time of resection. Patients will then be monitored for disease recurrence and other secondary outcomes.
A pharmaceutical composition that can be used to treat viral infections, particularly HIV. The composition comprises from about 250 mg to about 6000 mg of a benzimidazole derivative of the formula:wherein X is hydrogen, halogen, alkyl of less than 7 carbon atoms or alkoxy of less than 7 carbon atoms; n is a positive integer of less than 4; Y is hydrogen, chlorine, nitro, oxychloro, methyl or ethyl; and R is hydrogen or an alkyl group having from 1 to 8 carbon atoms, and R2 is 4-thiazolyl and the pharmaceutically acceptable organic or inorganic addition salts thereof. The preferred compound is thiabendazole. In the present invention it has been discovered that the compounds described above are useful for the inhibition of HIV and the treatment of HIV infection when used alone or in combination with other anti-viral agents. These compositions can prevent replication of the HIV virus, create virus resistance in the patient and prevent or delay infectability of cells with HIV virus and delay reappearance of the virus in the treated cells. These compositions are also effective against hepatitis and such as herpes, influenza and rhinoviruses and can be used in conjunction with other agents such as other anti-viral compounds or potentiators for the treatment of viral infections.
PCT No. PCT/FR80/00133 Sec. 371 Date Apr. 30, 1981 Sec. 102(e) Date Apr. 29, 1981 PCT Filed Aug. 29, 1980 PCT Pub. No. WO81/00577 PCT Pub. Date Mar. 5, 1981.Nucleic acid of reduced size and vector containing said nucleotidic sequence of which DNA codes an immunogenic peptidic sequence capable of inducing the generation of antibodies to the virus of viral hepatitis B. It comprises totally or partly the sequence of nucleotides represented in FIG. 3A. Application to the production by cloning in a bacterium of an immunogenic protein immunizing against hepatitis B, or application to the obtention of probes for the diagnosis of the presence of Dane particles in a serum.
The invention concretely relates to a traditional Chinese medicinal composition (Zhuwenqing) for treating swine fever, and a preparation method thereof. The traditional Chinese medicinal composition comprises, by weight, 10-30 parts of cactus, 2-4 parts of Herba Taraxaci, 2-7 parts of isatis root, 30-60 parts of red pear, 3-7 parts of honeysuckle flower, 2-5 parts of barbed skullcap herb, 20-60 parts of rock sugar, 2-5 parts of Malva crispa Linn. and 3-7 parts of wild chrysanthemum flower. The method comprises the following steps: chopping red pear and cactus, adding the chopped red pear and cactus, Herba Taraxaci, isatis root, honeysuckle flower, barbed skullcap herb, rock sugar, Malva crispa Linn. and wild chrysanthemum flower into a pot, adding clear water with the weight of 0.8-1.2 times the total weight of above raw materials, decocting by using slow fire until boiling, braising at a low baking temperature for 20min, removing residues, and cooling. The traditional Chinese medicinal composition is fast effective; the above obtained soup is sweet, so diseased pigs voluntarily take the soup, keep up spirits and want to move and eat green feeds 15min after taking the soup, and defecate 20min later.
Radiofrequency ablation and cryoablation for treatment of atrial fibrillation (AF) using percutaneous venous access at the groin is one of the most common procedures performed by cardiac electrophysiologists. However, compared to other catheter-based interventions, patients undergoing AF ablation pose a unique set of challenges. First, AF ablation requires multiple points of transfemoral venous access with large diameter sheaths, ranging in size from 8 French gauge (F) to 14F for cryoablation procedures. Second, operators are forced to balance the competing risk of thrombosis and bleeding in these patients. In order to minimize the risk of intraprocedural thrombosis, anticoagulation with heparin with a goal anticoagulation time (ACT) \>300-350 seconds is necessary. However, operators typically require ACTs to normalize prior to removal of sheaths and manual compression, which significantly delays hemostasis and ambulation. While reversal agents are an option, there is currently clinical equipoise on their role and safety in this setting and they require additional time to exert their full effect. Lastly, patients require at least 1-2 months of therapeutic oral anticoagulation after the procedure to mitigate ongoing stroke risk. These factors culminate in longer times to hemostasis and ambulation and raise concerns for post-procedure access related complications for patients undergoing AF ablation. PerClose Proglide has recently gained FDA approval for closure of percutaneous venous access sites for catheter-based interventions and remains the only commercially available solution for access sites \>14F inner diameter. Percutaneous closure of venotomy sites may facilitate rapid hemostasis without the need for reversal of anticoagulation, potentially attenuating bleeding risk. Additionally, typical bedrest times after percutaneous closure are based on data derived from arterial closure. Prior limited data, as well as frequent anecdotal reports, have suggested that earlier ambulation may be feasible. Because the venous circulation is a lower pressure system, it is possible that earlier than standard ambulation times after PerClose is both safe and feasible. However, a rigorous prospective investigation of the PerClose Proglide device in the context of AF ablation has not been performed.
Objective: To quantify cerebral cortical and deep gray matter atrophy in patients with multiple sclerosis (MS) and explore its correlation with impairment in domains of cognitive function. Methods: Twenty patients with MS and 16 healthy controls (HC) matched for age, sex, and education level were included. Using FreeSurfer software, based on 3D-MRI technology, the differences in cortical thickness and deep gray matter volume between the two groups were comparatively analyzed. A neuropsychological scale that included six domains of cognitive function was scored on both study groups to analyze the correlation between cortical thickness and volume of deep gray matter in MS patients with impairment in cognitive function domains. Results: Impairment in domains of cognitive function: cognitive impairment was present in 60% MS patients in this study, mainly manifesting as impairment of verbal memory, verbal fluency, visuospatial memory, and information processing speed function (all P<0.05). Of these, the majority had impaired visuospatial memory function (55.0%), and the least number of patients had impaired information processing speed (15.0%). Changes in cortical thickness: compared with the HC group, the MS group showed that cortical atrophy was mainly concentrated in the frontoparietal region, including significant thinning of cortical thickness in the left inferior parietal gyrus, right superior frontal gyrus, and the right superior parietal gyrus (all P<0.05). Among them, atrophy of the left inferior parietal gyrus was significantly positively correlated with the impairment of verbal memory, verbal fluency, and information processing speed (all P<0.05). There was a significant positive correlation between the right superior frontal gyrus atrophy and verbal memory, verbal fluency, and visuospatial memory impairment (all P<0.05). Changes in deep gray matter volume: compared with the HC group, deep gray matter volume in the MS group decreased significantly in the bilateral thalamus, bilateral putamen, bilateral pallidum (all P<0.01), and right nucleus accumbens (P<0.05). Among them, left thalamus atrophy was significantly positively correlated with visuospatial memory impairment (r=0.45, P=0.046), and left putamen atrophy was both significantly positively correlated with visuospatial memory (r=0.45, P=0.047) and information processing speed impairment (r=0.50, P=0.026). Conclusions: Early structural brain changes in MS are dominated by gray matter atrophy. Deep gray matter is more prominent than cortical atrophy.